Phase1/2study evaluating safety and efficacy of bortezomib-lenalidomid-dexamethasone induction therapy followed by lenalidomide-dexamethasone consolidation and lenalidomide maintenance for newly diagnosed patients with multiple myeloma eligible for stem cell transplantation.
Phase of Trial: Phase I/II
Latest Information Update: 12 May 2016
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 23 Oct 2015 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
- 26 Mar 2015 New trial record